A device designed to prevent stroke during carotid artery procedures is being pulled from hospital shelves because its tip can break off inside an artery, where it may cause the exact injury the device exists to prevent.
The FDA issued an early alert on July 24 about two Boston Scientific products: the ENROUTE Transcarotid Neuroprotection System and the ENROUTE Transcarotid Neuroprotection System Plus. Boston Scientific sent affected customers a letter on July 9 recommending they immediately stop using specific lots and return them.
According to the FDA, the problem is arterial sheath tip separation or partial tip separation during use. As of July 9, Boston Scientific had reported one serious injury and no deaths.
What an Early Alert Means
This is a newer FDA mechanism and its status is worth understanding, because it sits ahead of the recall process rather than inside it.
The agency says it issues an early alert "to notify the public of a potentially high-risk device issue" while it is still reviewing the information. No recall classification has been assigned. That means FDA has not yet formally graded the hazard, and readers should not infer a class from the alert's existence in either direction.
The practical significance is speed. Under the older approach, the public often learned of a device problem only after the classification process concluded, which can take weeks. Here the notice went out roughly two weeks after the manufacturer's letter, while the review continues.
Boston Scientific's letter instructed customers to "Immediately stop further use or distribution and segregate affected product," return it to the company, notify staff who use the devices, and contact any facility to which systems had been forwarded. FDA has published the full list of affected lots.
What the Device Does and Why a Broken Tip Is Serious
The ENROUTE system is used in transcarotid artery revascularization, a procedure to open a narrowed carotid artery, which is one of the main vessels supplying blood to the brain.
Its entire purpose is protective. The system reverses blood flow at the treatment site before a physician crosses the narrowed segment and while the blockage is being manipulated, so that debris dislodged during the procedure is carried away from the brain rather than toward it. Carotid procedures carry stroke risk precisely because plaque fragments can travel upstream, and flow reversal is the safeguard.
A tip that separates introduces a foreign body into the arterial system at the moment the patient is most vulnerable. The FDA states that tip separation may require endovascular or surgical retrieval of the retained fragment, and that complications associated with a retained tip include "embolism, stroke, transient ischemic attack, restenosis, or thrombosis."
Restenosis means the artery narrows again. Thrombosis means clot formation at the site. Both can require further intervention.
Retrieving a retained fragment is itself a procedure with risk, performed in a patient who has just undergone carotid intervention.
Who Is Affected and Who Is Not
This is hospital equipment. No patient owns one, stores one, or can check for one at home, and there is nothing for the general public to inspect or discard.
The people with a genuine stake are narrower. Patients scheduled for transcarotid artery revascularization at a facility that stocked affected lots have the most immediate interest, though hospitals receive these notices directly and remove product as routine practice. Patients who already underwent the procedure with an affected device are the group for whom the alert raises a real question.
For that second group, the relevant fact is reassuring in scale rather than in principle. One serious injury has been reported across the affected lots. Anyone who has had a carotid procedure and later developed new neurological symptoms should be evaluated regardless of this alert, because that is the standard advice after carotid intervention.
Symptoms that warrant emergency care include sudden weakness or numbness on one side of the body, sudden difficulty speaking or understanding speech, sudden vision loss in one eye, sudden severe headache, or sudden loss of balance or coordination. Those are stroke warning signs and require 911 rather than a call to a surgeon's office.
Patients with a history of carotid disease, prior stroke or transient ischemic attack, and those on antiplatelet therapy after a procedure should keep scheduled follow-up appointments rather than seeking urgent evaluation on the strength of this alert alone.
What Patients Can Reasonably Ask
For anyone with a carotid procedure scheduled, a short set of questions is appropriate and easy for a surgical team to answer.
Whether the facility used ENROUTE systems and, if so, whether its inventory has been checked against the affected lot list. Whether an alternative device or approach is available. Whether the procedure timing should change, which is a clinical judgment that depends on how urgently the narrowing needs treatment. Delaying a needed carotid procedure carries its own stroke risk, and that trade-off belongs with the surgeon rather than with a news article.
For anyone who has already had the procedure, asking at the next follow-up whether an affected lot was used is reasonable, and the facility should be able to determine that from the device identifier recorded in the operative note.
Nobody should stop antiplatelet or anticoagulant medication because of this alert. Doing so after a carotid procedure raises stroke risk substantially.
Patients and clinicians can report problems to FDA through MedWatch. Boston Scientific has directed U.S. customers with questions to its field action center at BSCFieldActionCenter@bsci.com or (763) 415-7708.
What Happens Next
The FDA says it is reviewing the issue and will update its alert page as significant new information becomes available. The next verifiable step would be a recall classification, which would indicate the agency's own hazard assessment.
What remains unknown is how many devices are affected, how many procedures used them, the root cause of the tip separation, whether the count of serious injuries rises as facilities review cases, and whether the action expands to additional lots. MedicalDaily will monitor FDA device recall and alert postings.
The bottom line: FDA has issued an early alert on Boston Scientific ENROUTE and ENROUTE Plus transcarotid systems after reports that the arterial sheath tip can separate during use, with one serious injury reported and no deaths. Patients scheduled for or recently treated with transcarotid revascularization are the group concerned. The reasonable action is to ask the surgical team whether affected lots were used, not to delay needed treatment. The central uncertainty is the cause and the eventual scope.
Developing Story Timeline
July 24, 2026: FDA publishes an early alert describing arterial sheath tip separation and stating it is reviewing a potentially high-risk device issue.
July 9, 2026: Boston Scientific notifies affected customers, recommending they stop use, segregate product, and return it. One serious injury and no deaths reported as of this date.
Frequently Asked Questions
What devices are affected? The Boston Scientific ENROUTE Transcarotid Neuroprotection System and ENROUTE Transcarotid Neuroprotection System Plus, in specific lots listed by FDA.
What is the problem? Reports of the arterial sheath tip separating, or partially separating, during use. A retained tip may require endovascular or surgical retrieval.
What harm can it cause? FDA lists embolism, stroke, transient ischemic attack, restenosis and thrombosis as complications associated with a retained tip.
Has anyone been hurt? Boston Scientific reported one serious injury and no deaths as of July 9, 2026.
Is this a recall? Not yet formally. FDA issued an early alert, which notifies the public before a recall classification is assigned while the agency reviews the issue.
Do I have this device at home? No. It is used by physicians during carotid procedures and is not a patient held product.
I am scheduled for a carotid procedure. What should I ask? Whether the facility used ENROUTE systems, whether inventory was checked against the affected lots, and whether an alternative is available. Do not delay needed treatment without your surgeon's input.
I had the procedure already. What should I do? Ask at your next follow up whether an affected lot was used. Seek emergency care for any stroke warning signs, and do not stop antiplatelet medication.
